660822-43-5

Basic information

• Product Name: 1H-Indazole-3-carboxamide, N-[4-(2-oxo-1-pyrrolidinyl)phenyl]-
• CAS NO: 660822-43-5
• Molecular Formula: C18H16N4O2
• Molecular Weight: 320.351
• Mol File: 660822-43-5.mol

Chemical Properties

• CAS DataBase Reference: 1H-Indazole-3-carboxamide, N-[4-(2-oxo-1-pyrrolidinyl)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indazole-3-carboxamide, N-[4-(2-oxo-1-pyrrolidinyl)phenyl]-(660822-43-5)
• EPA Substance Registry System: 1H-Indazole-3-carboxamide, N-[4-(2-oxo-1-pyrrolidinyl)phenyl]-(660822-43-5)

Safety Data

• Hazardous Substances Data: 660822-43-5(Hazardous Substances Data)

Upstream product

• 13691-22-0 1-(4-aminophenyl)pyrrolidin-2-one 
• 4498-67-3 1H-Indazole-3-carboxylic acid 

Relevant articles and documents

1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS MAPKAP KINASE MODULATORS

The invention provides compounds of the formula: (I) for use in the prophylaxis or treatment of a disease state or condition mediated by a MAPKAP kinase: wherein A is a bond or a group CH2; R1 is a carbocyclic or heterocyclic group having from 3 to 12 ring members; R3, R4, R5 and R6 are the same or different and are each selected from hydrogen, halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group Ra -Rbwherein Ra is a bond, 0, CO, X1C(X2), C(X2)Xl, X1C(X2)X1, S, SO, S02, NRc, SO2NRc or NRcS02; and Rb is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono or di-C1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C1-8 hydrocarbyl group may optionally be replaced by 0, S, SO, SO2, NRc, X1C(X2), C(X2)X1 or X1C(X2)X1; Rc is hydrogen or C1-4hydrocarbyl; and X1 is O, S or NRc and X2 is =O, =S or =NRc.

Indazole-derivatives as factor Xa inhibitors

The present invention relates to compounds of the formulae I and Ib wherein R0 ; R1 ; R2 ;Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formulae I and Ib, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.